leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 22:47:44 - browse：92

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What should King Charles tell the public about his cancer?

focus

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

In Spain, a hospital brews its own CAR

SEC charges former device maker CEO with $41 million fraud

Medical mystery: When a cough is not just a cough

Three trends to watch in biotech in 2024

HCA sued by state AG for quality issues at Mission Health

leisure time

leisure time

entertainment

Cancer drug shortages should be causing more outrage

Christmas in the PICU brings some surprising joy

Medical records are filled with copy

A disappointing year of Humira biosimilars

After affirmative action ruling, medical educators look to 'holistic review'

Industry veterans launch new biotech VC with $310M

Continuity nursing helped my family in our darkest PICU moments

Medicare Advantage beneficiaries sue Humana over algorithm use

Guidelines to prevent youth baseball injuries need more muscle

Gilead might be held responsible for not developing a drug

Wikipedia

Carvykti CAR

Three trends to watch in biotech in 2024

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Why health records don't always know when patients are dead

Medicare Advantage proposed rates disappoint insurers

Why health records don't always know when patients are dead

Wikipedia

hotspot

focus

focus